Business headlines from the Apex backend, organized by sectors and major public companies for faster market scanning.
A report says Nvidia is investing in a deal structure linked to Perplexity’s rapid growth and future chip demand, with Nvidia CEO Jensen Huang arguing the economics are not inherently self-referential.
THE APEX TIMES
THE APEX TIMES
A Goldman Sachs executive said the rise of artificial intelligence (AI) is changing what junior bankers learn on the job, pointing to hiring and employment trends that show young workers in AI-exposed roles have faced sharper declines.
THE APEX TIMES
A new market analysis argues that Pfizer is emphasizing near-term savings while deferring the core question of whether its medicines are gaining traction until the end of the decade.
THE APEX TIMES
A Yahoo Finance report said NVIDIA topped Q2 expectations and guided for sharply higher fiscal 2028 revenue growth, intensifying demand for ETFs that give investors exposure to NVIDIA without concentrating risk in a single stock.
THE APEX TIMES
The CRM maker reported quarterly earnings that more than doubled as investment gains helped lift results, while revenue grew more than 10% and management increased its forward view for fiscal 2027.
THE APEX TIMES
A strong quarter driven by NVIDIA’s newest Blackwell-based chips helped the company beat market expectations, while investors are also watching the company’s next platform shift tied to “Vera Rubin,” expected to play a larger role in the coming quarter.
THE APEX TIMES
A broad lift in indexes tracked fresh momentum in US semiconductor bellwether Nvidia after investors judged its latest results to be stronger than expected, even as attention quickly shifted to the Federal Reserve’s Jackson Hole meeting.
THE APEX TIMES
The deal with dozens of U.S. states centers on allegations that Meta’s platforms contributed to a youth mental health crisis, with the company agreeing to sweeping changes that could reshape how it manages teen-facing features and safety tools.
THE APEX TIMES
The approval of nipocalimab-aahu as the first treatment shown for warm autoimmune hemolytic anemia (wAIHA) gives Johnson & Johnson a new, narrowly targeted product in a rare autoimmune category.
